MJN Neuroserveis raises €750,000 to roll out device predicting epileptic seizures

- January 24, 2018

Catalonia startup MJN Neuroserveis closes its second round of funding totalling €750,000 to further develop its device aimed at predicting when epileptic seizures will occur.

Having reached €600,000 in December through the crowdfunding platform specialized in healthcare, Capital Cell, MJN Neuroserveis received an additional €150,000 from ENISA, a public company dependent on Ministry of Industry, Energy and Tourism, to close out the second round of funding.

MJN Neuroserveis creates real-time data collecting devices and Artificial Intelligence (AI) algorithms which adapt to each person and learn to predict and warn epileptic seizures. All data gets recorded on a cloud system providing experts full accurate information for their diagnostics.

The neuroscience startup will use the funds to carry out clinical trials on patients with epilepsy that utilizes a device that is capable of measuring the risk of seizures and that advises a patient with epilepsy in advance that a seizure will occur.

Predicting epileptic seizures

predicting epileptic seizures

David Blánquez

“We are in the final phase of development of the device and our intention is to begin commercialization in Spain in the second half of 2018,” David Blánquez, CEO of MJN told El Referente.

“We have managed to create a valid and reliable system that will greatly improve the quality of life and safety of people with epilepsy. The technological part has been the main challenge and the team of engineers, researchers in prediction algorithms and application developers, will also be increasing thanks to the injection of capital,” he added.

The device was designed to monitor EEG, stress, and pulse in real-time in order to predict epileptic seizures. It warns the owner when a seizure is coming, so he or she can take preventative safety measures. It is fully connected to a mobile app which instantly notifies the user’s status to family and/or caregivers.

MJN Neuroserveis’ non-invasive device is placed in the patient’s ear that monitors its encephalogram and predicts when a seizure will occur. All the information is sent to a smartphone where an application processes the data and sends the possible alerts.

The project is one of those selected by Tech4Health, an investment and acceleration platform by Ship2B for technological startups with a social impact in the health.

Tim Hinchliffe

Tim Hinchliffe the editor in chief at Novobrief. Previously, he was a reporter for The Ghanaian Chronicle in West Africa, and Colombia Reports in South America. Principal at Espacio.